A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

Study acronym: CLEAR-AbKD
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Apr 24, 2028 → Oct 13, 2028
See other at-risk trials from AstraZeneca

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Apr 24, 2028 to Oct 13, 2028 Show 4 more changesShow less
    • Trial sites expanded: 24 → 27 locations
    • Study completion pushed from Oct 15, 2029 to Apr 15, 2030
    • Eligibility criteria shortened, about 11 words
    • Secondary endpoints: details revised at 1 of 12 entries
  2. Re-verified, no change to tracked fieldsv4
  3. Study sites: 22 to 24v3
  4. Study sites: 21 to 22v2
  5. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
732 trials monitored
See 61 trials at risk
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
Trial Details
NCT Number NCT07571746
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Primary Membranous Nephropathy
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov